What is Minoxidil?

Minoxidil was originally developed as an oral antihypertensive (vasodilator) medication. Its hair growth-promoting effect was discovered serendipitously when patients experienced hypertrichosis (excessive hair growth) as a side effect. Today, it is the most clinically established topical treatment for androgenetic alopecia (male and female pattern baldness).

FDA-approved concentrations: 2% (women), 5% (men), and 5% foam.

Minoxidil MF

Mechanism of action (prodrug): Minoxidil itself is inactive as a hair growth stimulant. It must be converted by sulfotransferase enzymes (specifically SULT1A1) in the hair follicle to its active metabolite—Minoxidil Sulfate. This conversion is the rate-limiting step for efficacy.

Key limitation: Individual response to Minoxidil depends on endogenous sulfotransferase activity in hair follicles. Approximately 40% of patients are “low responders” due to insufficient enzyme activity.

What is Minoxidil Sulfate?

Minoxidil Sulfate is the active metabolite of Minoxidil. It is the direct-acting form that does not require enzymatic conversion in the hair follicle.

Primary advantage: By supplying the active metabolite directly, Minoxidil Sulfate bypasses the sulfotransferase-dependent activation step, potentially offering:

• More consistent response across different individuals

• Faster onset of action (no conversion delay)

• Potential efficacy in “Minoxidil non-responders” (those with low SULT1A1 activity)

Current regulatory status: Minoxidil Sulfate is not FDA-approved for hair loss treatment. It is available as a research chemical and cosmetic ingredient in some markets. Formulators must verify local regulatory status before product development.

Minoxidil Sulfate MF

Mechanism of Action Comparison